Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACP1 | P24666 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | FABP4 | P15090 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.43 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16053638 | 0.84 | ACP1 (0.44) | ACP1MEN1KMT2AMAPTRAB9A | |
| SCHEMBL25336108 | 0.82 | ALDH1A1 (0.60) | ACP1L3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL29569513 | 0.82 | ALDH1A1 (0.60) | ACP1L3MBTL1MEN1KMT2AMAPT | |
| SCHEMBL29748804 | 0.81 | MEN1 (0.65) | MEN1KMT2AMAPTRAB9AALDH1A1 | |
| SCHEMBL333559 | 0.81 | MEN1 (0.65) | MEN1KMT2AMAPTRAB9AALDH1A1 | |
| SCHEMBL4008576 | 0.81 | ACP1 (0.59) | ACP1L3MBTL1FABP4MEN1KMT2A | |
| SCHEMBL3304054 | 0.80 | S1PR2 (0.62) | ACP1L3MBTL1FABP4MEN1KMT2A | |
| SCHEMBL14670859 | 0.79 | L3MBTL1 (0.61) | ACP1L3MBTL1FABP4MEN1KMT2A | |
| SCHEMBL11016444 | 0.79 | ACP1 (0.58) | ACP1L3MBTL1FABP4MEN1KMT2A | |
| SCHEMBL8877167 | 0.79 | FABP4 (0.66) | ACP1L3MBTL1FABP4MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9850203-B2 | Autotaxin inhibitor compounds | PHARMAKEA, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850203-B2 | Autotaxin inhibitor compounds | PHARMAKEA, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20160214935-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | DF 2024 IP ACQUISITION, LLC | 2016-07-28 | — | — | US | disclosed |
| US-20160214935-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | DF 2024 IP ACQUISITION, LLC | 2016-07-28 | — | — | US | disclosed |
| WO-2015048301-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | PHARMAKEA, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
| US-7528134-B2 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-7498441-B2 | Biaryltetrahydroisoquinoline piperidines as selective MCH receptor antagonists for the treatment of obesity and related disorders | SCHERING CORPORATION (US) | 2009-03-03 | — | — | US | disclosed |
| EP-1601664-B1 | BIARYLTETRAHYDROISOQUINOLINE PIPERIDINES AS SELECTIVE MCH RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS | SCHERING CORP (US) | 2008-04-30 | — | — | EP | disclosed |
| EP-1709040-A2 | FIVE-MEMBERED HETEROCYCLIC COMPOUNDS AS INHIBITORS OF SRC FAMILY PROTEIN KINASE | Sirenade Pharmaceuticals AG (DE) | 2006-10-11 | — | — | EP | disclosed |
| CN-1777596-A | Biaryltetrahydroisoquinoline piperidines as selective mch receptor antagonists for the treatment of obesity and related disorders | SCHERING CORP (US) | 2006-05-24 | — | — | CN | disclosed |
| EP-1555264-A1 | Five-membered heterocyclic compounds as inhibitors of SRC family protein kinase. | Sireen AG (DE) | 2005-07-20 | — | — | EP | disclosed |
| EP-1509213-A2 | ACETAMIDES AND BENZAMIDES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | Abbott Laboratories (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20040267017-A1 | 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors | BAYER PHARMACEUTICALS CORPORATION | 2004-12-30 | — | — | US | disclosed |
| WO-2004078745-A1 | BIARYLTETRAHYDROISOQUINOLINE PIPERIDINES AS SELECTIVE MCH RECEPTOR ANTAGONISTS FOR THE TREATMENT OF OBESITY AND RELATED DISORDERS | SCHERING CORPORATION (US) | 2004-09-16 | — | — | WO | disclosed |
| US-20040176355-A1 | Biaryltetrahydroisoquinoline piperidines as selective MCH receptor antagonists for the treatment of obesity and related disorders | SCHERING CORPORATION | 2004-09-09 | — | — | US | disclosed |
| EP-1432706-A2 | 3-PYRIDYL OR 4-ISOQUINOLINYL THIAZOLES AS C17,20 LYASE INHIBITORS | Bayer Pharmaceuticals Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| US-20040029887-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2004-02-12 | — | — | US | disclosed |
| US-20030229094-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2003-12-11 | — | — | US | disclosed |
| WO-2003099266-A2 | ACETAMIDES AND BENZAMIDES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003027085-A2 | 3-PYRIDYL OR 4-ISOQUINOLINYL THIAZOLES AS C17,20 LYASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229094-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | CATSPER1, CYP19A1, PDE12 | ACP1 3831/4885L3MBTL1 4477/4885FABP4 3541/4885 |
| US-20040029887-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | CATSPER1, CYP19A1, PDE12 | ACP1 3831/4885L3MBTL1 4477/4885FABP4 3541/4885 |
| US-20040176355-A1 | Biaryltetrahydroisoquinoline piperidines as selective MCH receptor antagonists for the treatment of obesity and related disorders | MCHR1, MCHR2, MC4R | ACP1 2513/4885L3MBTL1 3376/4885FABP4 285/4885 |
| US-20040267017-A1 | 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors | CYP17A1, CYP21A2, HSD17B1 | ACP1 2932/4885L3MBTL1 2671/4885FABP4 3744/4885 |
| US-20160214935-A1 | AUTOTAXIN INHIBITOR COMPOUNDS | ENPP2, SERPINB1, SERPINE1 | ACP1 403/4885L3MBTL1 1789/4885FABP4 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.